North West Health, Biotech & Nutrition R&D Companies Directory

Our Future Health is a large-scale research organisation focused on the development of national health data infrastructure to support the early detection and prevention of disease. The company operates as a major research centre, coordinating large-scale longitudinal health studies to advance precision medicine and public health outcomes. Their work is primarily supported through direct government funding to establish core national research programmes.

The University of Liverpool is a leading research-intensive academic institution that actively translates fundamental scientific research into commercial and societal applications through extensive industrial collaboration. Their work spans diverse domains including digital twins for urban transport, climate modelling, healthcare diagnostics, and maritime decarbonisation. By leveraging cross-disciplinary expertise, the university bridges the gap between academic discovery and real-world implementation, frequently partnering with SMEs and large enterprises to address complex technical and environmental challenges.

Cellular Therapeutics is a biotechnology company specialising in the development of tumour-infiltrating lymphocyte (TIL) therapies for solid tumours, with a focus on manufacturing processes and clinical translation. Their work has evolved from early microfluidic cell processing tools to leading clinical trials of engineered TILs for ovarian cancer, supported by a strong network of academic, NHS, and industry partners.

Fotenix develops multispectral 3D imaging and cloud-based AI for precision agriculture, enabling automated crop monitoring, disease detection, and resource optimisation. The company has evolved from feasibility studies on fruit imaging to deploying digital platforms for glasshouse pest management, vertical farm control, and orchard precision fertigation.

AINOSTICS develops AI-powered software that analyses routine brain MRI scans to diagnose dementia earlier and more accurately. Their platform uses machine learning to detect micro-structural changes in tissue, providing quantitative biomarkers for disease stratification and treatment response. The company has progressed from early feasibility studies to FDA regulatory preparation and a major dementia mission grant.

QV Bioelectronics is a Manchester-based medical device start-up developing GRACE, a first-of-its-kind implantable electric field therapy device for treating glioblastoma and other aggressive brain tumours. The company's work has progressed from initial industrial research to preclinical validation and feasibility studies for paediatric brain cancers, aiming to translate the technology into first-in-human clinical trials. Their approach focuses on delivering focal, continuous electrotherapy to improve patient outcomes and quality of life compared to existing treatments.

The Christie NHS Foundation Trust is a specialist cancer centre that leads large-scale collaborative R&D initiatives to accelerate the adoption of Advanced Therapy Medicinal Products (ATMPs) within the NHS. Their work focuses on building infrastructure, standardising clinical processes, and developing digital systems for patient-reported outcomes to facilitate the delivery of complex cell and gene therapies. Through the iMATCH hub, they coordinate multi-stakeholder consortia involving academic, clinical, and commercial partners to overcome logistical and regulatory barriers to advanced treatment access.

The University of Central Lancashire (UCLan) is a research-intensive higher education institution that leverages its academic expertise to drive industrial innovation through collaborative R&D and knowledge transfer partnerships. Their work spans diverse domains including cybersecurity, advanced manufacturing, sustainable materials, and healthcare, often focusing on translating academic research into practical, commercialised solutions for UK industry. The university maintains a strong track record of leading complex, multi-partner projects that integrate technical development with societal and ethical frameworks.

Unilever UK Central Resources is the R&D arm of a global consumer goods leader, focusing on the development of sustainable, bio-based ingredients and circular economy solutions for home and personal care. Their work spans advanced biotechnology, material science, and digital modelling to replace petrochemical-derived components with renewable alternatives. Through extensive collaborative research, they address complex challenges in resource efficiency, waste valorisation, and sustainable manufacturing.

Garnett Farms Engineering develops autonomous robotic systems for dairy farming, focusing on cow cubicle bedding units that monitor moisture and temperature to optimise bedding dispensing and reduce mastitis infection. Their work has evolved from a feasibility study on carbon-neutral stall management to a large-scale R&D project building an intelligent robotic bedder. The company collaborates with the University of Liverpool and is primarily funded through Innovate UK grants.

Kinomica develops diagnostic tests based on phosphoproteomic protein activity signatures for precision cancer treatment selection. The company's technology aims to improve patient stratification for targeted therapies, reducing ineffective treatments and NHS costs. Their work has evolved from a companion diagnostic for acute myeloid leukaemia to a multi-drug treatment selection algorithm for various cancers.

Chromition develops ultra-bright photoluminescent polymer nanoparticles (Luminspheres) for medical diagnostics, initially for LED lighting but pivoted to cancer histopathology and genetic testing. Their technology enables simultaneous multi-colour staining of biomarkers in tissue biopsies, and they have built digital platforms for autonomous cancer screening. The company has evolved from materials research to translational clinical applications, with a focus on breast cancer diagnosis and rapid pharmacogenetic testing.

Videregen is a UK-based biotechnology company specialising in tissue-engineered therapies using stem cells and biological scaffolds. They develop treatments for rare life-threatening conditions such as bronchopleural fistula and complete DiGeorge syndrome, and aim to induce organ transplant tolerance. Their work has progressed from late-stage pre-clinical testing to manufacturing quality control, with a strong focus on clinical translation.

Lucid Group is a medical device developer specialising in continence care and rehabilitation technologies. They have developed portable biofeedback therapy for faecal incontinence, connected devices for child and dementia patient bladder/bowel continence, and a device for diagnosing core muscle imbalances. Their work increasingly incorporates digital health and sustainability goals, often leading collaborative R&D projects.

Genedrive is a molecular diagnostics company specialising in the development of rapid, point-of-care testing platforms for infectious diseases and pharmacogenetics. Their work focuses on overcoming the translational bottleneck between biomarker discovery and routine clinical implementation by creating decentralised, cartridge-based testing systems. Over time, the company has evolved from developing hardware for sample preparation to integrating complex genomic testing into NHS clinical pathways.

LCR Ventures (operating as LYVA Labs) is a Liverpool-based innovation catalyst and RTO that supports the commercialisation of health and life sciences research. They manage regional innovation clusters and accelerator programmes, bridging the gap between academic research, SMEs, and investment to accelerate drug discovery and medical technology development. Their work has evolved from specific AI-driven medical device research into a broader role as a strategic hub for regional and national health-tech acceleration.

Active Lancashire is a community organisation focused on improving public health through physical activity and workplace wellbeing. They have developed the 'Business Health Matters' programme, which uses a screening tool from the University of Central Lancashire to assess physical and mental health in working-age individuals. Their work has evolved from a small pilot to a large-scale deployment across Lancashire leisure centres, aiming to sustain employment and improve productivity.

Agsenze is a UK-based agritech company that develops sensor-based monitoring systems for livestock and crop management, using IoT, machine learning, and acoustic/optical sensors to improve animal welfare, crop yield, and pest control. Their work has evolved from aflatoxin detection to wearable IoT for poultry, smart coops, pest monitoring, dairy cow monitoring, and facial recognition for pig health.

Genus is a global leader in animal genetics, specialising in the application of advanced biotechnology and genomic selection to improve livestock productivity and sustainability. The company focuses on developing high-performance breeding programmes for the beef and pork sectors, leveraging gene editing and microbiome-driven breeding to enhance disease resistance and environmental efficiency. Their work bridges the gap between fundamental genetic research and commercial agricultural application to support global food security and decarbonisation goals.

Monument Therapeutics is a biotechnology company specialising in precision medicine for psychiatric and neurological conditions. They have developed a reformulated anti-inflammatory drug with enhanced blood-brain barrier penetration and a biomarker test to identify patients with cognitive impairment in schizophrenia who will respond to their drug MT1988. The company's work has evolved from preclinical proof-of-concept in neuroinflammation to manufacturing readiness for clinical studies.